• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by NuCana plc

    4/23/25 4:44:53 PM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NCNA alert in real time by email
    6-K 1 d926433d6k.htm 6-K 6-K
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    OF THE SECURITIES EXCHANGE ACT OF 1934

    For the month of April 2025

    (Commission File No. 001-38215)

     

     

    NUCANA PLC

    (Translation of registrant’s name into English)

     

     

    3 Lochside Way

    Edinburgh EH12 9DT

    United Kingdom

    (Address of registrant’s principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

    Form 20-F ☒   Form 40-F ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1): ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7): ☐

     

     
     


    Other Events

    On April 23, 2025, NuCana plc (the “Company”) held a General Meeting (the “GM”) at Lochside House, 3 Lochside Way, Edinburgh, EH12 9DT, United Kingdom. All of the resolutions set out in the Company’s notice of the GM dated March 18, 2025 and furnished on Form 6-K with the Securities and Exchange Commission on March 18, 2025 were duly proposed and passed.

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    NuCana plc
    By:   /s/ Hugh S. Griffith
    Name:   Hugh S. Griffith
    Title:   Chief Executive Officer

    Date: April 23, 2025

    Get the next $NCNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NCNA

    DatePrice TargetRatingAnalyst
    8/30/2024Outperform → Mkt Perform
    William Blair
    3/3/2022Outperform → Market Perform
    Cowen & Co.
    11/24/2021$10.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NCNA
    Leadership Updates

    Live Leadership Updates

    See more
    • NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors

      EDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr. Levy brings over 20 years of experience at global pharmaceutical companies, including Amgen and Bristol-Myers Squibb, and has a strong track record of leading clinical strategy and development efforts for numerous programs at all stages of development. "We are thrilled to welcome Dr. Levy to our Board of Directors," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "He is a recognized

      11/1/21 4:01:00 PM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer

      EDINBURGH, United Kingdom, Aug. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Jeffrey D. Bloss, M.D. as Chief Medical Officer. Dr. Bloss will be based in NuCana's US offices located outside Boston, MA. "We are delighted to welcome Jeff to the executive team at NuCana," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Jeff brings over two decades of experience leading clinical development and medical affairs at several biotechnology and pharmaceutical companies. His achievements include leading the development, approval and

      8/10/21 8:00:00 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NCNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NuCana plc

      SC 13G/A - NuCana plc (0001709626) (Subject)

      10/4/24 10:14:46 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by NuCana plc (Amendment)

      SC 13D/A - NuCana plc (0001709626) (Subject)

      2/27/24 4:29:36 PM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by NuCana plc (Amendment)

      SC 13G/A - NuCana plc (0001709626) (Subject)

      2/14/24 4:26:01 PM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NCNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $NCNA
    SEC Filings

    See more
    • NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

      Initiation of Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Remain on track for 2025 Anticipated Cash Runway Extended into Q4 2026 to Support Key Value-Driving Milestones and Complete the Expansion Study of NUC-7738 EDINBURGH, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the first quarter ended March 31, 2025 and provided an update on its clinical development prog

      6/2/25 4:01:00 PM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NuCana Prices $7 Million Registered Direct Offering

      EDINBURGH, United Kingdom, May 06, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company that focuses on significantly improving treatment outcomes for patients with cancer, announced that it has priced a registered direct offering consisting of 10,845,985 American Depository Shares, or ADSs, (or pre-funded warrants in lieu thereof) with each ADS (or pre-funded warrant) accompanied by (i) a Series A warrant to purchase one (1) ADS at an initial exercise price of $0.8068 per share and (ii) a Series B Warrant to purchase one (1) ADS at an initial exercise price of $1.61 per share. The combined public offering price of each ADS together with the accompa

      5/6/25 8:30:00 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

      Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025 Data from the Expansion Study to Support Interaction with FDA and Define Regulatory Strategy for NUC-7738 Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Anticipated Cash Runway Extended into Q3 2025 EDINBURGH, United Kingdom, March 20, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the fourth quarter and year ended December 31, 2024 and provided an update on its clinical development program with its two lead anti-cancer medicines. "Throughout 2024, we shared mul

      3/20/25 4:01:49 PM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by NuCana plc

      6-K - NuCana plc (0001709626) (Filer)

      6/2/25 4:36:34 PM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B4 filed by NuCana plc

      424B4 - NuCana plc (0001709626) (Filer)

      5/7/25 7:32:35 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by NuCana plc

      EFFECT - NuCana plc (0001709626) (Filer)

      5/6/25 12:15:12 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NCNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NuCana downgraded by William Blair

      William Blair downgraded NuCana from Outperform to Mkt Perform

      8/30/24 7:44:58 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NuCana downgraded by Cowen & Co.

      Cowen & Co. downgraded NuCana from Outperform to Market Perform

      3/3/22 6:12:40 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on NuCana with a new price target

      HC Wainwright & Co. reiterated coverage of NuCana with a rating of Buy and set a new price target of $9.00 from $10.00 previously

      11/24/21 6:13:12 AM ET
      $NCNA
      Biotechnology: Pharmaceutical Preparations
      Health Care